Natco Pharma Share Price
Sector: Biotechnology & Drugs
874.75 -8.70 (-0.98%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
869.45
Today’s High
883.10
52 Week Low
660.05
52 Week High
1638.35
875.15 -8.25 (-0.93%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
870
Today’s High
885
52 Week Low
726.80
52 Week High
1639
Key Metrics
- Market Cap (In Cr) 15667.64
- Beta 0.73
- Div. Yield (%) 0.68
- P/B 2.08
- TTM P/E 7.59
- Peg Ratio 0.07
- Sector P/E 28.32
- D/E 0
- Open Price 883.1
- Prev Close 883.45
Natco Pharma Analysis
Price Analysis
-
1 Week0.55%
-
3 Months14.62%
-
6 Month-35.78%
-
YTD-36.32%
-
1 Year-13.42%
Risk Meter
- 53% Low risk
- 53% Moderate risk
- 53% Balanced Risk
- 53% High risk
- 53% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 1
- 1
- 1
- 1
- Buy
- 1
- 2
- 3
- 3
- Hold
- 2
- 1
- 1
- 1
- Sell
- 2
- 2
- 2
- 2
- Strong Sell
- 0.00
- 0.00
- 0.00
- 1
- Total
- 6
- 6
- 7
- 8
Natco Pharma News
Q4 results today: IRCTC, Deepak Nitrate, SAIL, Cummins, Bata India on May 28
2 min read . 28 May 2025Buy or sell: Ganesh Dongre of Anand Rathi recommends three shares to buy
2 min read . 30 Mar 2025Eli Lilly launches its blockbuster weight loss drug Mounjaro in India
3 min read . 21 Mar 2025Natco Pharma Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2025
- Total Revenue
- 4429.5
- Selling/ General/ Admin Expenses Total
- 594.5
- Depreciation/ Amortization
- 235.2
- Other Operating Expenses Total
- 949.2
- Total Operating Expense
- 2468.7
- Operating Income
- 1960.8
- Net Income Before Taxes
- 2291.4
- Net Income
- 1885.4
- Diluted Normalized EPS
- 105.26
- Period
- 2025
- Total Assets
- 8630.8
- Total Liabilities
- 1023.8
- Total Equity
- 7607
- Tangible Book Valueper Share Common Eq
- 409.85
- Period
- 2025
- Cashfrom Operating Activities
- 1696.8
- Cashfrom Investing Activities
- -1414.5
- Cashfrom Financing Activities
- -210.7
- Net Changein Cash
- 49.6
- Period
- 2024
- Total Revenue
- 3998.8
- Selling/ General/ Admin Expenses Total
- 1227
- Depreciation/ Amortization
- 186.8
- Other Operating Expenses Total
- 30.9
- Total Operating Expense
- 2431.4
- Operating Income
- 1567.4
- Net Income Before Taxes
- 1673.5
- Net Income
- 1388.3
- Diluted Normalized EPS
- 77.42
- Period
- 2024
- Total Assets
- 6906.3
- Total Liabilities
- 1053.2
- Total Equity
- 5853.1
- Tangible Book Valueper Share Common Eq
- 316.01
- Period
- 2024
- Cashfrom Operating Activities
- 1211.6
- Cashfrom Investing Activities
- -1032.7
- Cashfrom Financing Activities
- -246.9
- Net Changein Cash
- -61.5
- Period
- 2023
- Total Revenue
- 2707.1
- Selling/ General/ Admin Expenses Total
- 914.3
- Depreciation/ Amortization
- 163.8
- Other Operating Expenses Total
- 11.4
- Total Operating Expense
- 1930.1
- Operating Income
- 777
- Net Income Before Taxes
- 861.9
- Net Income
- 715.3
- Diluted Normalized EPS
- 38.48
- Period
- 2023
- Total Assets
- 5657.4
- Total Liabilities
- 783.6
- Total Equity
- 4873.8
- Tangible Book Valueper Share Common Eq
- 256.81
- Period
- 2023
- Cashfrom Operating Activities
- 849.1
- Cashfrom Investing Activities
- -477.1
- Cashfrom Financing Activities
- -363
- Net Changein Cash
- 20.8
- Period
- 2022
- Total Revenue
- 1944.8
- Selling/ General/ Admin Expenses Total
- 819.2
- Depreciation/ Amortization
- 142.6
- Other Operating Expenses Total
- 17.2
- Total Operating Expense
- 1823.9
- Operating Income
- 120.9
- Net Income Before Taxes
- 202.2
- Net Income
- 170
- Diluted Normalized EPS
- 7.35
- Period
- 2022
- Total Assets
- 5109.1
- Total Liabilities
- 845.5
- Total Equity
- 4263.6
- Tangible Book Valueper Share Common Eq
- 226.31
- Period
- 2022
- Cashfrom Operating Activities
- 46.5
- Cashfrom Investing Activities
- -5.3
- Cashfrom Financing Activities
- 34.8
- Net Changein Cash
- 85.3
- Period
- 2021
- Total Revenue
- 2052.1
- Selling/ General/ Admin Expenses Total
- 803.1
- Depreciation/ Amortization
- 116.9
- Other Operating Expenses Total
- 11.8
- Total Operating Expense
- 1562.8
- Operating Income
- 489.3
- Net Income Before Taxes
- 579.6
- Net Income
- 440.9
- Diluted Normalized EPS
- 22.82
- Period
- 2021
- Total Assets
- 4791.9
- Total Liabilities
- 670.3
- Total Equity
- 4121.6
- Tangible Book Valueper Share Common Eq
- 225.53
- Period
- 2021
- Cashfrom Operating Activities
- 298.8
- Cashfrom Investing Activities
- -103.3
- Cashfrom Financing Activities
- -185.7
- Net Changein Cash
- 6
- Period
- 2020
- Total Revenue
- 1915
- Selling/ General/ Admin Expenses Total
- 746.7
- Depreciation/ Amortization
- 99.8
- Other Operating Expenses Total
- 23.5
- Total Operating Expense
- 1432.2
- Operating Income
- 482.8
- Net Income Before Taxes
- 568.7
- Net Income
- 460.8
- Diluted Normalized EPS
- 24.54
- Period
- 2020
- Total Assets
- 4587.8
- Total Liabilities
- 814.3
- Total Equity
- 3773.5
- Tangible Book Valueper Share Common Eq
- 206.77
- Period
- 2020
- Cashfrom Operating Activities
- 417.3
- Cashfrom Investing Activities
- -167
- Cashfrom Financing Activities
- -250.8
- Net Changein Cash
- -8.5
- Period
- 2019
- Total Revenue
- 2094.5
- Selling/ General/ Admin Expenses Total
- 741.4
- Depreciation/ Amortization
- 81
- Other Operating Expenses Total
- 10.1
- Total Operating Expense
- 1378.5
- Operating Income
- 716
- Net Income Before Taxes
- 824.7
- Net Income
- 644.4
- Diluted Normalized EPS
- 34.31
- Period
- 2019
- Total Assets
- 4303.1
- Total Liabilities
- 814.1
- Total Equity
- 3489
- Tangible Book Valueper Share Common Eq
- 190.44
- Period
- 2019
- Cashfrom Operating Activities
- 668.8
- Cashfrom Investing Activities
- -612.2
- Cashfrom Financing Activities
- -50.9
- Net Changein Cash
- 6.6
- Period
- 2025-03-31
- Total Revenue
- 1221
- Selling/ General/ Admin Expenses Total
- 159.4
- Depreciation/ Amortization
- 98.3
- Other Operating Expenses Total
- 264.3
- Total Operating Expense
- 771.2
- Operating Income
- 449.8
- Net Income Before Taxes
- 505.9
- Net Income
- 406.6
- Diluted Normalized EPS
- 22.7
- Period
- 2025-03-31
- Total Assets
- 8630.8
- Total Liabilities
- 1023.8
- Total Equity
- 7607
- Tangible Book Valueper Share Common Eq
- 409.85
- Period
- 2025-03-31
- Cashfrom Operating Activities
- 1696.8
- Cashfrom Investing Activities
- -1414.5
- Cashfrom Financing Activities
- -210.7
- Net Changein Cash
- 49.6
- Period
- 2024-12-31
- Total Revenue
- 474.8
- Selling/ General/ Admin Expenses Total
- 141.6
- Depreciation/ Amortization
- 47
- Other Operating Expenses Total
- 211.6
- Total Operating Expense
- 483
- Operating Income
- -8.2
- Net Income Before Taxes
- 163.7
- Net Income
- 133
- Diluted Normalized EPS
- 7.43
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 1371.1
- Selling/ General/ Admin Expenses Total
- 151.5
- Depreciation/ Amortization
- 45.8
- Other Operating Expenses Total
- 237.7
- Total Operating Expense
- 612.6
- Operating Income
- 758.5
- Net Income Before Taxes
- 818.2
- Net Income
- 677.3
- Diluted Normalized EPS
- 37.81
- Period
- 2024-09-30
- Total Assets
- 8244.7
- Total Liabilities
- 1094.8
- Total Equity
- 7149.9
- Tangible Book Valueper Share Common Eq
- 385.93
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 1137
- Cashfrom Investing Activities
- -881.7
- Cashfrom Financing Activities
- -219.1
- Net Changein Cash
- 34.2
- Period
- 2024-06-30
- Total Revenue
- 1362.6
- Selling/ General/ Admin Expenses Total
- 142
- Depreciation/ Amortization
- 44.1
- Other Operating Expenses Total
- 235.6
- Total Operating Expense
- 601.9
- Operating Income
- 760.7
- Net Income Before Taxes
- 803.6
- Net Income
- 668.5
- Diluted Normalized EPS
- 37.32
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 1068.3
- Selling/ General/ Admin Expenses Total
- 142.5
- Depreciation/ Amortization
- 55.5
- Other Operating Expenses Total
- 285.9
- Total Operating Expense
- 626.5
- Operating Income
- 441.8
- Net Income Before Taxes
- 477.6
- Net Income
- 386.3
- Diluted Normalized EPS
- 21.57
- Period
- 2024-03-31
- Total Assets
- 6906.3
- Total Liabilities
- 1053.2
- Total Equity
- 5853.1
- Tangible Book Valueper Share Common Eq
- 316.01
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1211.6
- Cashfrom Investing Activities
- -1032.7
- Cashfrom Financing Activities
- -246.9
- Net Changein Cash
- -61.5
- Period
- 2023-12-31
- Total Revenue
- 758.6
- Selling/ General/ Admin Expenses Total
- 121.9
- Depreciation/ Amortization
- 44.2
- Other Operating Expenses Total
- 206.4
- Total Operating Expense
- 534.7
- Operating Income
- 223.9
- Net Income Before Taxes
- 256.3
- Net Income
- 212.7
- Diluted Normalized EPS
- 11.88
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Natco Pharma Technical
Moving Average
SMA
- 5 Day879.36
- 10 Day874.6
- 20 Day850.38
- 50 Day834.42
- 100 Day955.59
- 300 Day1200.27
Natco Pharma Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Jubilant Pharmova
- 1184.8
- 12.45
- 1.06
- 1309
- 616.85
- 18887.98
- Caplin Point Laboratories
- 2129.1
- -23.3
- -1.08
- 2636
- 1221
- 16161.97
- Natco Pharma
- 874.75
- -8.7
- -0.98
- 1638.35
- 660.05
- 15667.64
- Sanofi India
- 6180.2
- -28.75
- -0.46
- 7593.6
- 4145.9
- 14190.34
- Granules India
- 525.9
- -5.3
- -1
- 724.55
- 401.35
- 12726.84
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Jubilant Pharmova
- 34.99
- 2.97
- 6.87
- 5.64
- Caplin Point Laboratories
- 30.64
- 5.73
- 21.81
- 26.11
- Natco Pharma
- 8.39
- 2.08
- 18.55
- 30.39
- Sanofi India
- 41.85
- 16.57
- 32.83
- 21.53
- Granules India
- 26.91
- 3.46
- 17.54
- 11.64
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 28-May-25
- Audited Results
- 12-Feb-25
- Quarterly Results & Interim Dividend
- 12-Nov-24
- Quarterly Results & Interim Dividend
- 12-Aug-24
- Quarterly Results & Interim Dividend
- 27-May-24
- Audited Results
- 14-Feb-24
- Quarterly Results & Interim Dividend
- 14-Nov-23
- Quarterly Results & Interim Dividend
- 09-Aug-23
- Quarterly Results & Interim Dividend
- 29-May-23
- Audited Results
- 08-Mar-23
- Buy Back of shares
- Meeting Date
- Announced on
- Purpose
- 28-Mar-24
- 22-Feb-24
- POM
- 29-Sept-23
- 05-Sept-23
- AGM
- 27-Mar-22
- 22-Feb-22
- POM
- -
- 12-Aug-24
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 12-Feb-25
- 18-Feb-25
- 18-Feb-25
- 1.5
- 12-Nov-24
- 27-Nov-24
- 27-Nov-24
- 1.5
- 12-Aug-24
- 23-Aug-24
- 23-Aug-24
- 3
- 14-Feb-24
- 26-Feb-24
- 26-Feb-24
- 1.25
- 15-Nov-23
- 24-Nov-23
- 24-Nov-23
- 1.25
- 09-Aug-23
- 22-Aug-23
- 22-Aug-23
- 7
- 09-Feb-23
- 21-Feb-23
- 21-Feb-23
- 1.25
- 10-Nov-22
- 22-Nov-22
- 21-Nov-22
- 0.75
- 10-Aug-22
- 22-Aug-22
- 19-Aug-22
- 3.5
- 14-Feb-22
- 25-Feb-22
- 24-Feb-22
- 2


